Drugs / Decorin
Decorin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03924544 | Sep 2019 → Sep 2021 | open-angle glaucoma | Cairo University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02865031 | Aug 2015 → Jul 2016 | proliferative vitreoretinopathy | Cairo University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03924544 ↗ |
| Known as | Bone proteoglycan ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650389 ↗ |
| Known as | Pg-s2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650389 ↗ |
| Action | Inhibit | “a transforming growth factor ß (TGFß) inhibitor” NCT02865031 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant decorin protein” NCT02865031 ↗ |
| Route | Intravitreal | “is to be injected intravitreally” NCT02865031 ↗ |